Plasma matrix metalloproteinase-9 levels, MMP-9 gene haplotypes, and cardiovascular risk in obese subjects

Molecular Biology Reports

Volumn 43, Issue 6, 2016, Pages 463-471

  Luizon, Marcelo R ^a   Belo, Vanessa A ^b   Fernandes, Karla S ^c   Andrade, Vanessa L ^c   Tanus Santos, Jose E ^b   Sandrim, Valeria C ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Nucleo de Pos Graduacao e Pesquisa   (Brazil)

Author keywords

Haplotypes; Matrix metalloproteinase (MMP) 9; Metabolic risk factors; Obesity; Polymorphisms; Tissue inhibitor of matrix metalloproteinase (TIMP) 1

Indexed keywords

GELATINASE B; GLUCOSE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; BIOLOGICAL MARKER; MMP9 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; METABOLIC RISK FACTOR; MIDDLE AGED; MMP 9 GENE; OBESITY; PREDICTIVE VALUE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASE; ENZYMOLOGY; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84966441164     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-016-3993-z     Document Type: Article

References (32)

1. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37(6):375–536. doi:10.1080/10409230290771546
2. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene I (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107(12):1579–1585. doi:10.1161/01.CIR.0000058700.41738.12
3. Das SK, Ma L, Sharma NK (2015) Adipose tissue gene expression and metabolic health of obese adults. Int J Obes (Lond) 39(5):869–873. doi:10.1038/ijo.2014.210
4. Dandona P, Ghanim H, Monte SV, Caruana JA, Green K, Abuaysheh S, Lohano T, Schentag J, Dhindsa S, Chaudhuri A (2014) Increase in the mediators of asthma in obesity and obesity with type 2 diabetes: reduction with weight loss. Obesity (Silver Spring) 22(2):356–362. doi:10.1002/oby.20524
5. Phillips CM, Tierney AC, Perez-Martinez P, Defoort C, Blaak EE, Gjelstad IM, Lopez-Miranda J, Kiec-Klimczak M, Malczewska-Malec M, Drevon CA, Hall W, Lovegrove JA, Karlstrom B, Riserus U, Roche HM (2013) Obesity and body fat classification in the metabolic syndrome: impact on cardiometabolic risk metabotype. Obesity (Silver Spring) 21(1):E154–E161. doi:10.1002/oby.20263
6. Ahima RS, Lazar MA (2013) Physiology. The health risk of obesity—better metrics imperative. Science. doi:10.1126/science.1241244
7. Despres JP (2012) Body fat distribution and risk of cardiovascular disease: an update. Circulation 126(10):1301–1313. doi:10.1161/CIRCULATIONAHA.111.067264
8. Yang W, Kelly T, He J (2007) Genetic epidemiology of obesity. Epidemiol Rev 29:49–61. doi:10.1093/epirev/mxm004
9. Morgan AR, Zhang B, Tapper W, Collins A, Ye S (2003) Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med (Berl) 81(5):321–326. doi:10.1007/s00109-003-0441-z
10. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99(14):1788–1794
11. Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, Izidoro-Toledo TC, Ferraz KC, Tanus-Santos JE (2012) Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 36(1):69–75. doi:10.1038/ijo.2011.169
12. Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G (1995) Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 309(Pt 1):299–306
13. Duellman T, Warren C, Yang J (2014) Single nucleotide polymorphism-specific regulation of matrix metalloproteinase-9 by multiple miRNAs targeting the coding exon. Nucleic Acids Res 42(9):5518–5531. doi:10.1093/nar/gku197
14. Lacchini R, Jacob-Ferreira AL, Luizon MR, Coeli FB, Izidoro-Toledo TC, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W Jr, Tanus-Santos JE (2010) Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 411(23–24):1940–1944. doi:10.1016/j.cca.2010.08.008
15. Flegal KM, Kit BK, Orpana H, Graubard BI (2013) Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309(1):71–82. doi:10.1001/jama.2012.113905
16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart A, National Heart L, Blood I (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404
17. Metzger IF, Luizon MR, Lacchini R, Tanus-Santos JE (2012) Genetic variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects. DNA Cell Biol 31(4):504–510. doi:10.1089/dna.2011.1388
18. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70(2):425–434. doi:10.1086/338688
19. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978–989. doi:10.1086/319501
20. Menashe I, Rosenberg PS, Chen BE (2008) PGA: power calculator for case-control genetic association analyses. BMC Genet 9:36. doi:10.1186/1471-2156-9-36
21. Andrade VL, Petruceli E, Belo VA, Andrade-Fernandes CM, Caetano Russi CV, Bosco AA, Tanus-Santos JE, Sandrim VC (2012) Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. Clin Biochem 45(6):412–415. doi:10.1016/j.clinbiochem.2012.01.008
22. Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczkowska-Plaksej J, Bednarek-Tupikowska G, Mazurek W (2008) Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int J Obes (Lond) 32(5):763–771. doi:10.1038/sj.ijo.0803794
23. Derosa G, Ferrari I, D’Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF (2008) Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 15(4):219–224. doi:10.1080/10623320802228815
24. Berg G, Miksztowicz V, Schreier L (2011) Metalloproteinases in metabolic syndrome. Clin Chim Acta 412(19–20):1731–1739. doi:10.1016/j.cca.2011.06.013
25. Berg G, Schreier L, Miksztowicz V (2014) Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: pathophysiological aspects. Horm Mol Biol Clin Investig 17(2):79–87. doi:10.1515/hmbci-2013-0069
26. Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE (2009) Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403(1–2):173–177. doi:10.1016/j.cca.2009.02.013
27. Sheu WH, Chang TM, Lee WJ, Ou HC, Wu CM, Tseng LN, Lang HF, Wu CS, Wan CJ, Lee IT (2008) Effect of weight loss on proinflammatory state of mononuclear cells in obese women. Obesity (Silver Spring) 16(5):1033–1038. doi:10.1038/oby.2008.37
28. Jung UJ, Choi MS (2014) Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15(4):6184–6223. doi:10.3390/ijms15046184
29. Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97. doi:10.1038/nri2921
30. Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444(7121):875–880. doi:10.1038/nature05487
31. Andrade VL, Fernandes KS, Bosco AA, Tanus-Santos JE, Sandrim VC (2012) Functional polymorphism located in MMP-9 gene promoter is strongly associated with obesity. DNA Cell Biol 31(6):1054–1057. doi:10.1089/dna.2011.1526
32. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE (1999) Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 30(12):2612–2616